Substance Use Disorders Edition 2

This CME meets the DEA-mandated eight hours of Medication Access and Training Expansion (MATE) Act.

add

Free for AAFP members


Learning Objectives

  1. Implement evidence-based guidelines and principles into the evaluation and treatment of patients with substance use disorders.

  2. Demonstrate a patient-centered approach to the care of patients with substance use disorder with attention to destigmatizing language.

  3. Discuss harm-reduction philosophy and approach to caring for patients and communities.

  4. Demonstrate skills and techniques that are appropriate for use in patients with other substance use disorders.

Additional details

Alcohol Use Disorder: Screen, Diagnose, Treat and Support
Joyce Troxler, MD

Considering the Patient Perspective
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM; Brandon George

Emerging Psychoactive Substances: Fentanyl, Kratom and Xylazine
Jasleen Salwan, MD, MPH

Harm Reduction and Addressing Stigma
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM

Harm Reduction: Any Positive Change
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM

Intake Assessment and Care Coordination
David O’Gurek, MD

Interpretation of Toxicology Results
Anika Alvanzo, MD, MS, DFASAM, FACP

Managing Common Comorbidities: Sleep, Anxiety and Depression
Sky Lee, MD, AAHIVS

Principles of Motivational Interviewing
David O’Gurek, MD

Smoking Cessation and E-Cigarettes
Marie-Elizabeth Ramas, MD, FAAFP

Stimulant Use Disorder: The Tools in Our Toolbox
Hannah Snyder, MD

Substance Use Disorders Edition 2 Reflection and Translation to Practice® (t2p®)
David O’Gurek, MD

The Evidence Base for Treatment of OUD
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM

The Impact of Drug Policy on SUDs
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM; David O’Gurek, MD; Jason Glenn, PhD

Trauma-informed Care
David O’Gurek, MD

Treatment of OUD with Buprenorphine Part 1: Initiation of Treatment
Nicole Gastala, MD

Treatment of OUD With Buprenorphine Part 2: Follow-up Visits and Maintenance
Margaret Lowenstein, MD, M. Phil., MSHP

What Is Addiction?
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM

*Enhance your patient care today and earn up to two additional AAFP Prescribed credits for when you complete the Translation to Practice® (t2p®) process.

David O’Gurek, MD—Course director

Speakers:

  • Anika Alvanzo, MD, MS, DFASAM, FACP
  • Brandon George
  • David O’Gurek, MD—Course director
  • Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM
  • Hannah Snyder, MD
  • Jasleen Salwan, MD, MPH
  • Jason Glenn, PhD
  • Joyce Troxler, MD
  • Margaret Lowenstein, MD, M.Phil., MSHP
  • Marie-Elizabeth Ramas, MD, FAAFP
  • Nicole Gastala, MD
  • Sky Lee, MD, AAHIVS

CME credit statement

3 in 4

People with substance use disorder do not receive the treatment they need.

National Survey on Drug Use and Health, November 2023

Related CME

Substance Use Disorders